相似文献
1
Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need.2019年冠状病毒病（COVID-19）治疗的临床试验：对迫切需求的快速响应。
Sci China Life Sci. 2020 May;63(5):774-776. doi: 10.1007/s11427-020-1660-2. Epub 2020 Feb 29.
2
Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?我们是否有足够的证据将氯喹/羟氯喹用作应对新冠病毒病的公共卫生万能药？
Clinics (Sao Paulo). 2020;75:e1928. doi: 10.6061/clinics/2020/e1928. Epub 2020 May 8.
3
Hydroxychloroquine for Coronavirus: The Urgent Need for a Moratorium on Prescriptions.用于治疗冠状病毒的羟氯喹：迫切需要暂停处方使用
Am J Med. 2020 Sep;133(9):1007-1008. doi: 10.1016/j.amjmed.2020.05.005. Epub 2020 Jun 2.
4
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.支持瑞德西韦治疗新型冠状病毒感染的论据。
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
5
COVID-19: Important Therapy Considerations and Approaches in this Hour of Need.COVID-19：危难时刻的重要治疗考量与方法
Pharmacotherapy. 2020 May;40(5):379-381. doi: 10.1002/phar.2396. Epub 2020 May 5.
6
[Not Available].[无可用内容]。
Rev Med Suisse. 2020 Mar 25;16(687):606-607.
7
COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?新冠疫情：药物制剂与药物递送专家能提供什么？
Pharm Dev Technol. 2020 Jul;25(6):649. doi: 10.1080/10837450.2020.1764670.
8
Favipiravir, an antiviral for COVID-19?法匹拉韦，一种用于治疗新冠肺炎的抗病毒药物？
J Antimicrob Chemother. 2020 Jul 1;75(7):2013-2014. doi: 10.1093/jac/dkaa171.
9
Chloroquine and hydroxychloroquine in covid-19.氯喹和羟氯喹在2019冠状病毒病中的应用
BMJ. 2020 Apr 8;369:m1432. doi: 10.1136/bmj.m1432.
10
Use of herbal drugs to treat COVID-19 should be with caution.使用草药治疗新冠病毒疾病时应谨慎。
Lancet. 2020 May 30;395(10238):1689-1690. doi: 10.1016/S0140-6736(20)31143-0. Epub 2020 May 15.
引用本文的文献
1
Antiviral Activity of Medicinal Plants against Human Coronavirus: a systematic scoping review of and experimentations.药用植物抗人冠状病毒的抗病毒活性：系统范围评价与实验研究。
J Tradit Chin Med. 2022 Jun;42(3):332-343. doi: 10.19852/j.cnki.jtcm.2022.03.002.
2
Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (M) as Potential COVID-19 Therapies.针对严重急性呼吸综合征冠状病毒2型主要蛋白酶（M）的药物和天然产物的计算性重新利用作为潜在的新冠肺炎治疗方法
Front Mol Biosci. 2022 Mar 14;9:781039. doi: 10.3389/fmolb.2022.781039. eCollection 2022.
3
A urinary proteomic landscape of COVID-19 progression identifies signaling pathways and therapeutic options.COVID-19 进展的尿蛋白质组学图谱确定了信号通路和治疗选择。
Sci China Life Sci. 2022 Sep;65(9):1866-1880. doi: 10.1007/s11427-021-2070-y. Epub 2022 Mar 10.
4
Exploration of severe Covid-19 associated risk factor in China: Meta-analysis of current evidence.中国严重 COVID-19 相关风险因素的探索：当前证据的荟萃分析。
Int J Clin Pract. 2021 Dec;75(12):e14900. doi: 10.1111/ijcp.14900. Epub 2021 Oct 5.
5
Knowledge, Attitudes, and Practices Regarding COVID-19 among Healthcare Workers in Uganda: A Cross-Sectional Survey.乌干达医护人员对 COVID-19 的认知、态度和实践：一项横断面调查。
Int J Environ Res Public Health. 2021 Jun 30;18(13):7004. doi: 10.3390/ijerph18137004.
6
Large variations in disease severity, death and ICU admission of 2993 patients infected with SARS-CoV-2: The potential impact of genetic vulnerability.2993 例感染 SARS-CoV-2 患者的疾病严重程度、死亡和 ICU 入院率存在较大差异：遗传易感性的潜在影响。
J Infect Public Health. 2021 Jul;14(7):886-891. doi: 10.1016/j.jiph.2021.04.008. Epub 2021 Apr 22.
7
Assessment of nitric oxide (NO) potential to mitigate COVID-19 severity.评估一氧化氮（NO）减轻新冠病毒疾病（COVID-19）严重程度的潜力。
Virusdisease. 2021 Sep;32(3):589-594. doi: 10.1007/s13337-021-00702-6. Epub 2021 Jun 3.
8
The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants.新型冠状病毒2年15个月的临床经验：治疗方法与辅助剂的文献综述
Antioxidants (Basel). 2021 May 31;10(6):881. doi: 10.3390/antiox10060881.
9
Molecular scaffolds from mother nature as possible lead compounds in drug design and discovery against coronaviruses: A landscape analysis of published literature and molecular docking studies.从大自然母亲中寻找分子支架作为冠状病毒药物设计和发现的潜在先导化合物：已发表文献和分子对接研究的分析。
Microb Pathog. 2021 Aug;157:104933. doi: 10.1016/j.micpath.2021.104933. Epub 2021 May 11.
10
Thymoquinone: A Promising Natural Compound with Potential Benefits for COVID-19 Prevention and Cure.胸腺醌：一种有前途的天然化合物，具有预防和治疗 COVID-19 的潜力。
Drug Des Devel Ther. 2021 May 3;15:1819-1833. doi: 10.2147/DDDT.S308863. eCollection 2021.
本文引用的文献
1
More than 80 clinical trials launch to test coronavirus treatments.80多项临床试验启动以测试新冠病毒治疗方法。
Nature. 2020 Feb;578(7795):347-348. doi: 10.1038/d41586-020-00444-3.
2
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
3
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
4
Effect of integrated traditional Chinese medicine and western medicine on the treatment of severe acute respiratory syndrome: A meta-analysis.中西医结合治疗重症急性呼吸综合征的效果：一项Meta分析。
Pharm Pract (Granada). 2007 Jan;5(1):1-9. doi: 10.4321/s1886-36552007000100001.
5
Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.洛匹那韦/利托那韦治疗严重急性呼吸综合征：一项多中心回顾性匹配队列研究。
Hong Kong Med J. 2003 Dec;9(6):399-406.
Zotero 插件